Psychedelics Are Going Mainstream. Are You Ready For It?
- Date: Monday June 16th
- Time: 1:45 PM - 2:45 PM ET
- Location: Boston Convention & Exhibition Center Room 251
The therapeutic use of psychedelics is no longer a pipe dream – they are on the verge of potentially transforming the way we treat brain health disorders. As companies progress psychedelic therapies into phase three clinical studies for brain health disorders like anxiety, depression, PTSD, etc., the implications for healthcare are immense. Are patients, physicians, policymakers, and payers ready for it? This panel will explore the exciting future of psychedelic medicine, discussing how stakeholders can prepare for the regulatory, financial, and societal shifts that will come with it. Featuring insights from key opinion leaders including a leading pharmaceutical drug developer, a psychiatrist, professional organization representative, patient representative, and a healthcare payer. Panelists will explore critical questions such as: How do we ensure equitable access to these treatments? What are the challenges in scaling them for broad therapeutic use? And, how can we integrate them into existing healthcare systems?
Meet the panelists & Moderator
Dr. Moira Gunn
Host of NPR's 'Tech Nation'; Director of the Bio-Entrepreneurship Program at the University of San Francisco
Sharmin Ghaznavi, MD, PhD, MD, PhD
Associate Director, Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, Harvard Medical School
Daniel Karlin, MD, MA
Chief Medical Officer, MindMed
Michael Kobernick, MD, MD
Senior Medical Director, Blue Cross Blue Sheild of Michigan
Steffen Thirstrup, MD, PhD
Chief Medical Officer, European Medicines Agency (EMA)
Katie M.. Walker, LCSW
Patient Advocate; Licensed Certified Social Worker, Registered Play Therapist, Patient; Indigo Counseling
BIO International 2025
Bringing together industry experts to discuss the next wave of innovation in biotech.
See more with LifeSci Communications
We are committed to helping our partners transform complex science into moving stories that demand—and get—attention.
